Healthcare Industry News: Ion Beam Applications
News Release - June 15, 2009
Positron Announces the Addition of Northeast Business Director Peter Webner RT(N), CNMTINDIANAPOLIS--(HSMN NewsFeed)--Positron Corporation (OTCBB: POSC.OB ) announced today that Peter Webner RT(N), CNMT has joined Positron in the capacity of Northeast Regional Business Director. Mr. Webner brings over 20 years of experience in the Nuclear Medicine field. Mr. Webner has built extensive relationships in the field and is active in promoting nuclear medicine on a global basis.
"Peter’s overall expertise and clinical background in Nuclear Medicine will significantly enhance our management team and bottom line," said John Zehner, COO and VP of Sales. "I have known Peter for the past decade, his understanding of the industry, clinical knowledge and his ability to always be ahead of the curve has made him a tremendous addition to our team. Peter has the proven ability to assist both our customers and companies in all facets of their patient care, business development and revenue growth.”
Most recently, Mr. Webner served as Vice President Product Development for IBA North America – Ion Beam Applications is a global provider of healthcare solutions with PET and SPECT applications. During his nine year tenure at IBA, he launched the North East market and had significant impact on increasing revenue, margins and earnings. He led initiatives to increase new product development efforts, such as, a mobile Rb-82 generator sharing plan for Cardiac imaging and was extensively involved in product acquisitions for IBA.
“This is an incredible opportunity to expand my career in Nuclear Medicine. Positron has an outstanding line of products,” stated Peter Webner. “The recently approved 510k Attrius PET scanner, the Pulse® SPECT scanner, the new Tech-Assist™, and the new Nuclear Pharm-Assist® provide imaging and automation solutions. The entire product line utilizes state of the art technology to deliver practical, safe, and cost effective care and work flow solutions to our industry for both Cardiac and Oncology applications.”
Mr. Webner currently serves on the Society of Nuclear Medicine’s PET Utilization Task force, Reimbursement Committee, and APC Task force. He also serves on the Academy of Molecular Imaging’s Referring Physician Education Workgroup, Reimbursement, and Health Economics Workgroup.
Positron is a molecular imaging company with a focus on Nuclear Cardiology. Positron utilizes its proprietary product line to provide unique solutions to the Nuclear Medicine community ranging from imaging to radiopharmaceutical distribution. Positron has four primary products: the Attrius™, a PET imaging device; the Pulse®, a SPECT imaging device; the Nuclear Pharm-Assist®, an automated radiopharmaceutical distribution device; and the Tech-Assist™, a radiopharmaceutical patient injection shield. Over 150 Positron products are installed in hospitals and medical offices around the world. More information about Positron is available at www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance and may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
For further information please contact Positron Corporation at (866)-613-7587.
Source: Positron Corporation
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.